MannKind Corp. (MNKD)

[JLS]

Martin Shkreli is not MannKind's problem.

Afrezza is what Afrezza is, and it would be very difficult to find any diabetic who ever heard of Martin Shkreli. Afrezza got approved and its label is designed as the FDA requires -- and that's the end of it.

MannKind's and Sanofi's problem is the difficulty of marketing Afrezza to both the insurance companies and the end users. Solve those problems then Afrezza will probably sell and your shares will likely go up.

Now we get to the investors' problems -- people like yourself. Their problem is that they invested in the company (and regularly average down) based only on hope and faith. Too bad for them. They should have waited for performance. I guess that's the price they pay for speculation.